05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£19,762,559 |
Nicolas Loebel |
3,538,991 |
£447,430 |
Junaid Bajwa |
1,193,697 |
£150,917 |
Jean Duvall |
1,163,529 |
£147,103 |
Jean Charest |
353,356 |
£44,674 |
Simon Sinclair |
256,327 |
£32,407 |
Carolyn Cross |
118,091,377 |
£14,930,124 |
M&G Plc |
40,588,235 |
£5,131,512 |
Robert Cross |
25,858,400 |
£3,269,240 |
Albemarle Life Sciences Fund |
15,105,882 |
£1,909,815 |
CRUX Asset Management |
9,298,090 |
£1,175,544 |
Chelverton Asset Management |
7,957,311 |
£1,006,032 |
11:55 |
11,136 @ 13.39p |
11:48 |
11 @ 12.50p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research